Newsroom | 24886 results

TYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in non-invasive therapeutic devices, today announced that it intends to effect a reverse stock split of its common stock, par value $0.001 per share (the “common stock”) at a ratio of 1 post-split share for every 10 pre-split shares. The reverse stock split will become effective at 4:05 p.m. ET on Monday, August 11, 2025. The Company’s common stock will c...

MURFREESBORO, Tenn.--(BUSINESS WIRE)--National HealthCare Corporation (NYSE American: NHC), the nation's oldest publicly traded senior health care company, announced today net operating revenues for the quarter ended June 30, 2025 totaled $374,910,000 compared to $300,658,000 for the quarter ended June 30, 2024, an increase of 24.7%. The increase in net operating revenues for the second quarter of 2025 compared to the second quarter of 2024 was due to an 9.6% increase in same-facility net opera...

MOBILE, Ala.--(BUSINESS WIRE)--TruBridge, Inc. (NASDAQ: TBRG), a healthcare solutions company, today announced financial results for the second quarter and six months ended June 30, 2025. Second Quarter 2025 Highlights* All comparisons are to the quarter ended June 30, 2024, unless otherwise noted Total bookings of $25.6 million compared to $23.3 million Total revenue of $85.7 million compared to $85.6 million Recurring revenue represented 95% of total revenue Financial Health revenue of $54.3...

明尼阿波利斯--(BUSINESS WIRE)--(美国商业资讯)-- Edison®组织摧毁术系统及新型组织摧毁术治疗平台的研发企业HistoSonics今日宣布，由一批全球知名的私人和公共投资者组成的联盟将以管理层主导的方式收购其多数股权，投资方包括K5 Global、Bezos Expeditions、Wellington Management以及其他新老投资者。此次交易对HistoSonics的估值约为22.5亿美元，将助力公司加速Edison系统在新临床适应症及全球市场的增长。 HistoSonics将继续由总裁兼首席执行官Mike Blue及其管理团队领导。交易完成后，Blue先生还将担任董事会主席一职。 Blue先生表示：“作为一家公司，我们始终专注于速度、规模，以及为患者提供比现有方案更优选择的迫切使命。这批新合作伙伴支持那些定义品类、变革整个行业的企业。他们的支持将为我们注入动力，加速发展势头，拓展至新的临床适应症，惠及全球更多急需我们突破性疗法的患者。” HistoSonics计划在初始聚焦的肝肿瘤之外，将业务扩展至肾、胰腺和前列腺肿瘤适应症，其长期愿景是让组织摧毁...

明尼亞波里斯--(BUSINESS WIRE)--(美國商業資訊)-- Edison®組織摧毀術系統及新型組織摧毀術治療平台的研發企業HistoSonics今日宣布，由一批全球知名的私人和公共投資人組成的聯盟將以管理層主導的方式收購其多數股權，投資方包括K5 Global、Bezos Expeditions、Wellington Management以及其他新投資人和現有投資人。此次交易對HistoSonics的估值約為22.5億美元，將協助公司加快Edison系統在新臨床適應症及全球市場的成長。 HistoSonics將繼續由總裁兼執行長Mike Blue及其管理團隊領導。交易完成後，Blue先生還將擔任董事長一職。 Blue先生表示：「身為一家公司，我們始終專注於速度、規模，以及為病患提供比現有方案更優選擇的迫切使命。這批新合作夥伴支援那些定義品類、變革整個產業的企業。他們的支援將為我們注入動力，加大發展動力，擴大至新的臨床適應症，嘉惠全球更多亟需我們突破性療法的病患。」 HistoSonics計畫在初始聚焦的肝腫瘤之外，將業務擴充至腎、胰腺和攝護腺腫瘤適應症，其長期願景是讓組織摧...

ミネアポリス--(BUSINESS WIRE)--（ビジネスワイヤ） -- Edison®（エジソン）ヒストトリプシー・システムおよび新規ヒストトリプシー治療プラットフォームの開発企業であるヒストソニックスは、K5グローバル、ベゾス・エクスペディションズ、ウエリントン・マネージメント、および新規・既存の投資家を含むグローバルに認知された民間・公的投資家のシンジケートによる経営陣主導の過半数株式取得を発表しました。取引によりヒストソニックスは約22億5000万ドルの評価を受け、新規臨床適応とグローバル市場におけるエジソン・システムの成長加速が可能になります。 ヒストソニックスは、社長兼最高経営責任者（CEO）のマイク・ブルーと経営陣が引き続き率いていきます。ブルーは取引完了後、取締役会会長を兼務します。 「当社が企業として徹底して重視してきたのは、スピードと規模、そして今あるどの選択肢よりも優れた治療法を患者にいち早く提供することです」とブルーは述べています。「新たなパートナーとなるこのグループは、業界全体を変革するカテゴリー定義企業を支援してきました。支援により企業としての水準が向上...

ADDISON, Texas--(BUSINESS WIRE)--Concentra Group Holdings Parent, Inc. (“Concentra,” the “Company,” “we,” “us,” or “our”) (NYSE: CON), the nation’s largest provider of occupational health services, today announced results for its second quarter ended June 30, 2025, the declaration of a cash dividend, and raised guidance for FY 2025. “Concentra delivered strong results in the second quarter, building on our solid start to 2025,” said Keith Newton, Chief Executive Officer of Concentra. “Our resul...

SANTA MONICA, Calif.--(BUSINESS WIRE)--FIGS, Inc. (NYSE: FIGS) (the “Company”), the global leading healthcare apparel brand dedicated to improving the lives of healthcare professionals, today released its second quarter 2025 financial results and published a financial highlights presentation on its investor relations website at ir.wearfigs.com/financials/quarterly-results/. Second Quarter 2025 Financial Highlights Net revenues were $152.6 million, an increase of 5.8% year over year, primarily d...

NEW YORK--(BUSINESS WIRE)--DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health and medical transportation services, today announced financial and operating results for the quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights Total revenue for the second quarter of 2025 was $80.4 million, compared to $164.9 million in the second quarter of 2024. This decline was due to the planned wind-down of migrant-related programs. GAA...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its second quarter 2025 results of operations. “This was a very successful second quarter for Gilead, including the FDA approval for Yeztugo as the world’s first twice-yearly HIV prevention option,” said Daniel O’Day, Gilead’s Chairman and Chief Executive Officer. “Our strong growth this quarter was driven by Biktarvy, Descovy, Trodelvy and Livdelzi, reflecting the diversity of our portfolio. As we enter...